MPS solutions that address industry needs

Developing a novel biological model – or testing the technologies that drive them – often begins with a roadblock. First, an entire suite of peripherial systems must be developed to accommodate the innovation being tested. B/MSC’s revolutionary STARTER Kit eliminates that roadblock as the first "all-in-one" OoC platform which is interoperability-focused, standardised and modular. Our STARTER Kit is powered by the TOP Platform, so if your technology is already ISO22916 compliant, it is compatible!

We can use the STARTER Kit to help you:

• Translate innovations from prototype to scalable solutions
• Standardize and validate your existing technology
• Rapidly develop your technology towards new applications
• Test and itegrate key microphysiological systems

B/MSC not only offers this unique and innovative solution, but also the knowledge and expertise to help adapt it to your needs. We can support the design of new microfluidic routing, integrate our in-house biological models, and help with standardised testing according to your target specifications.

Achieving high throughput and highly effective testing is another key challenge in MPS. With the Smart Well Plate, B/MSC offers a 96-well plate format that allows for experiment parallelisation. Equipped with Micro Electrode Arrays (MEAs), integrated sensors, actuators, and microfluidics that more closely mimic human tissues and reactions, the Smart Well Plate significantly enhances experiment automation.

Use the Smart Well Plate to:

• Increase experiment efficacy and throughput
• Perform time-relevant, multi-organ studies and dose in real time with very small samples
• Enable multi-organ testing and connect them through microfluidics
• Increase scalability and reduce costs of plate manufacturing

B/MSC can support a partner’s ambitions at any Technological Readiness Level (TRL). From as early as the Proof of Principle phase, all the way through to the Application phase, our expertise and technologies can drive development faster, with more accuracy, and in less time than ever before.

In the later stages of drug development, rejection due to lack of efficacy is a major risk. The loss of time and resources if such a rejection occurs are significant. B/MSC enables a higher translatability from preclinical to late clinical trials with highly effective and accurate, preclinical biological models. Our gut and liver models – and especially these two combined – offer highly effective studies.

Use our Biological models to:

• Perform highly translatable multi-organ studies during drug discovery
• Utilise our expertise in organoids and cell line models for new product development
• Study immune response applications and host/microbiome interactions
• Extend studies to other ex-plant tissues (skin, liver, etc)
• Enable a one-stop solution for effective and accurate drug discovery

B/MSC is one of the first organisations to use an explant tissue intestinal explant barrier chip (IEBC) to offer the full complexity of human intestinal tissue to the earliest stages of drug discovery. Our large and versatile testing facility enables us to develop the precise models needed for effective drug development, including aerobic/anaerobic interfaces or multi-organ models.